World's first public dengue immunization program starts in the Philippines
- Details
- Category: Sanofi
Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major launch event, hosted by the Department of Health (DoH) of the Philippines,
Pandemic influenza vaccine receives positive CHMP opinion
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional approval of Pandemic Live Attenuated Influenza Vaccine (P/LAIV).
Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome
- Details
- Category: AstraZeneca
AstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT). Brilinta (ticagrelor) is now preferred over clopidogrel for the management of patients with acute coronary syndrome (ACS) who have received a coronary stent and in non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) patients treated with medical therapy alone (Class IIa LoE: B-R).
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban)
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL.
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE).
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.
AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
- Details
- Category: AstraZeneca
AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
More Pharma News ...
- Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
- Abbott's Absorb, the first fully dissolving heart stent, earns positive review by FDA advisory committee
- Pfizer celebrates a year of achievements in 2015 annual review
- FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer
- Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
- Pfizer commences $5 billion accelerated share repurchase
- AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation